Evidence map›Paper›PMID 39125679›Full record

ArticleInternational journal of molecular sciences2024

4-Phenylbutyric Acid Treatment Reduces Low-Molecular-Weight Proteinuria in a

Ana Perdomo-Ramírez, Elena Ramos-Trujillo, Jose David Machado, Victor García-Nieto, Glorián Mura-Escorche, Félix Claverie-Martin, RenalTube Group

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ana Perdomo-RamírezUnidad de Investigacion, Hospital Universitario Nuestra Señora de Candelaria, Instituto de Investigacion Sanitaria de Canarias (IISC), 38010 Santa Cruz de Tenerife, Spain.ORCID 0000-0002-2562-2119
Elena Ramos-TrujilloUnidad de Investigacion, Hospital Universitario Nuestra Señora de Candelaria, Instituto de Investigacion Sanitaria de Canarias (IISC), 38010 Santa Cruz de Tenerife, Spain.
Jose David MachadoSeccion Medicina, Departamento de Medicina Fisica y Farmacologia, Facultad de Ciencias de la Salud, Universidad de La Laguna, 38200 Santa Cruz de Tenerife, Spain.
Victor García-NietoUnidad de Nefrologia Pediatrica, Hospital Universitario Nuestra Señora de Candelaria, 38010 Santa Cruz de Tenerife, Spain.
Glorián Mura-EscorcheUnidad de Investigacion, Hospital Universitario Nuestra Señora de Candelaria, Instituto de Investigacion Sanitaria de Canarias (IISC), 38010 Santa Cruz de Tenerife, Spain.
Félix Claverie-MartinUnidad de Investigacion, Hospital Universitario Nuestra Señora de Candelaria, Instituto de Investigacion Sanitaria de Canarias (IISC), 38010 Santa Cruz de Tenerife, Spain.ORCID 0000-0003-2468-3267
RenalTube Group

Funding

Asociacion de la Enfermedad de Dent (ASDENT) D18-003Instituto de Salud Carlos III PI17/00153 and PI20/00652
6 · The paper itself

Abstract

Dent disease-1 (DD-1) is a rare X-linked tubular disorder characterized by low-molecular-weight proteinuria (LMWP), hypercalciuria, nephrolithiasis and nephrocalcinosis. This disease is caused by inactivating mutations in the

Indexed as

Chloride ChannelsDisease Models, AnimalGene Knock-In TechniquesPhenylbutyratesProteinuriaAnimalsDent DiseaseGenetic Diseases, X-LinkedHumansMaleMiceMutationNephrolithiasis4-phenylbutyric acidChloride ChannelsCLC-5 chloride channelPhenylbutyratesDent disease-1knock-in mouse modellow-molecular-weight proteinuriasodium 4-phenylbutyrate

Identifiers

PMID39125679
PMCPMC11311629

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.